Familial hypercholesterolaemia: a pressing issue for European health care

Area of Science:

• Cardiovascular Medicine
• Genetics
• Public Health

Background:

• Familial hypercholesterolaemia (FH) is a common genetic disorder with a prevalence of 1/200-1/500, significantly increasing coronary heart disease (CHD) mortality, particularly in younger individuals.
• Despite established European Atherosclerosis Society (EAS) and UK National Institute of Health and Clinical Excellence (NICE) guidelines, FH remains under-diagnosed and poorly managed in most European countries, including the UK, with fewer than 15% of cases identified.
• This diagnostic gap results in a substantial number of undiagnosed cases, over 100,000 in the UK alone, missing opportunities for timely intervention.

Purpose of the Study:

• To review the current situation regarding FH diagnosis and management in the UK.
• To identify and propose solutions for breaking down implementation barriers for FH guidelines across Europe.
• To emphasize the benefits of early diagnosis and treatment, including genetic screening and statin therapy, for reducing CHD mortality.

Main Methods:

• Review of current European Atherosclerosis Society (EAS) and UK National Institute of Health and Clinical Excellence (NICE) guidelines.
• Analysis of the implementation status of FH diagnostic and management strategies in the UK and selected European countries.
• Discussion of the role of genetic testing and cascade screening in FH management.
• Exploration of the impact of early statin treatment on mortality rates.

Main Results:

• Despite NICE guidelines recommending genetic testing and cascade screening since 2008, systematic diagnosis of FH in England lags behind Scotland, Wales, Northern Ireland, and other European countries with established screening programs.
• Early treatment with statins is an effective and cost-efficient method for reducing mortality in FH patients to levels comparable to the general population.
• Genome technologies offer significant potential for improved FH diagnosis and patient benefit.

Conclusions:

• There is a critical need to address the under-diagnosis and poor management of familial hypercholesterolaemia across Europe.
• Implementing systematic screening programs and leveraging genetic testing are crucial for early identification and intervention.
• Early statin therapy and the application of new genomic technologies are essential for reducing the high mortality associated with FH and improving patient outcomes.